The fibrinogen assay kit has the advantages of high sensitivity and specificity, wide detection range, convenient and efficient operation, diverse sample types, strict and reliable quality control, and wide application scenarios. The following is a specific introduction:
High sensitivity and specificity: advanced technologies such as immunoturbidimetry, double antibody sandwich method, or enzyme-linked immunosorbent assay (ELISA) are used to accurately detect the concentration of fibrinogen (Plg) in human serum or plasma. The detection range usually covers 75pg/ml to 2500pg/ml, ensuring accurate capture of low concentration samples. Wide detection range: Supports multiple types of sample detection, including serum, plasma, tissue homogenate, and cell culture supernatant, to meet the needs of different clinical and scientific research scenarios. For example, in liver disease monitoring, liver synthesis function can be evaluated through plasma testing; In tumor research, the expression level of fibrinogen in tissue homogenates can be analyzed.
Easy and efficient operation: Suitable for fully automatic analyzers (such as specific protein analyzers), batch sample processing can be achieved, and a single test can be completed within 20 minutes, significantly reducing laboratory turnover time and improving work efficiency.
.Diverse sample types: In addition to conventional serum and plasma, some test kits also support the detection of special samples such as urine and cerebrospinal fluid, providing more flexible research tools for the development of disease biomarkers (such as tumors and cardiovascular diseases).
.Strict and reliable quality control: Equipped with abnormal value quality control plasma, ensuring that the coefficient of variation (CV) of the test results is ≤ 5%, in line with clinical laboratory standards.
. For example, by dynamically monitoring the consumption of fibrinogen during thrombolytic therapy, the risk of bleeding caused by excessive fibrinolysis can be avoided.Widely applicable scenarios:
Clinical diagnosis: Distinguishing between bleeding and thrombus risk. For example, low fibrinogen levels indicate congenital fibrinolysis defects or disseminated intravascular coagulation (DIC), while high concentrations reflect increased fibrinolysis activity and increased risk of deep vein thrombosis.
.Treatment monitoring: Guide the dosage adjustment of thrombolysis (such as urokinase) or anti fibrinolytic therapy (such as tranexamic acid), evaluate drug efficacy through concentration changes, and balance hemostasis and thrombus risk.
. Research analysis: Support research on the regulation of the fibrinolytic system, development of disease biomarkers, and development of new drugs, providing standardized detection tools for the molecular mechanisms of thrombosis or bleeding.source:http://en.zjikon.com/news1082649.html